Skip to main content
Journal cover image

Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.

Publication ,  Journal Article
Slack, J; Albert, MH; Balashov, D; Belohradsky, BH; Bertaina, A; Bleesing, J; Booth, C; Buechner, J; Buckley, RH; Ouachée-Chardin, M; Drabko, K ...
Published in: J Allergy Clin Immunol
January 2018

BACKGROUND: Rare DNA breakage repair disorders predispose to infection and lymphoreticular malignancies. Hematopoietic cell transplantation (HCT) is curative, but coadministered chemotherapy or radiotherapy is damaging because of systemic radiosensitivity. We collected HCT outcome data for Nijmegen breakage syndrome, DNA ligase IV deficiency, Cernunnos-XRCC4-like factor (Cernunnos-XLF) deficiency, and ataxia-telangiectasia (AT). METHODS: Data from 38 centers worldwide, including indication, donor, conditioning regimen, graft-versus-host disease, and outcome, were analyzed. Conditioning was classified as myeloablative conditioning (MAC) if it contained radiotherapy or alkylators and reduced-intensity conditioning (RIC) if no alkylators and/or 150 mg/m2 fludarabine or less and 40 mg/kg cyclophosphamide or less were used. RESULTS: Fifty-five new, 14 updated, and 18 previously published patients were analyzed. Median age at HCT was 48 months (range, 1.5-552 months). Twenty-nine patients underwent transplantation for infection, 21 had malignancy, 13 had bone marrow failure, 13 received pre-emptive transplantation, 5 had multiple indications, and 6 had no information. Twenty-two received MAC, 59 received RIC, and 4 were infused; information was unavailable for 2 patients. Seventy-three of 77 patients with DNA ligase IV deficiency, Cernunnos-XLF deficiency, or Nijmegen breakage syndrome received conditioning. Survival was 53 (69%) of 77 and was worse for those receiving MAC than for those receiving RIC (P = .006). Most deaths occurred early after transplantation, suggesting poor tolerance of conditioning. Survival in patients with AT was 25%. Forty-one (49%) of 83 patients experienced acute GvHD, which was less frequent in those receiving RIC compared with those receiving MAC (26/56 [46%] vs 12/21 [57%], P = .45). Median follow-up was 35 months (range, 2-168 months). No secondary malignancies were reported during 15 years of follow-up. Growth and developmental delay remained after HCT; immune-mediated complications resolved. CONCLUSION: RIC HCT resolves DNA repair disorder-associated immunodeficiency. Long-term follow-up is required for secondary malignancy surveillance. Routine HCT for AT is not recommended.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Allergy Clin Immunol

DOI

EISSN

1097-6825

Publication Date

January 2018

Volume

141

Issue

1

Start / End Page

322 / 328.e10

Location

United States

Related Subject Headings

  • Young Adult
  • Virus Diseases
  • Treatment Outcome
  • Prognosis
  • Mutation
  • Male
  • Kaplan-Meier Estimate
  • Infant
  • Humans
  • Hematopoietic Stem Cell Transplantation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Slack, J., Albert, M. H., Balashov, D., Belohradsky, B. H., Bertaina, A., Bleesing, J., … Primary Immunodeficiency Treatment Consortium, . (2018). Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. J Allergy Clin Immunol, 141(1), 322-328.e10. https://doi.org/10.1016/j.jaci.2017.02.036
Slack, James, Michael H. Albert, Dmitry Balashov, Bernd H. Belohradsky, Alice Bertaina, Jack Bleesing, Claire Booth, et al. “Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.J Allergy Clin Immunol 141, no. 1 (January 2018): 322-328.e10. https://doi.org/10.1016/j.jaci.2017.02.036.
Slack J, Albert MH, Balashov D, Belohradsky BH, Bertaina A, Bleesing J, et al. Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. J Allergy Clin Immunol. 2018 Jan;141(1):322-328.e10.
Slack, James, et al. “Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.J Allergy Clin Immunol, vol. 141, no. 1, Jan. 2018, pp. 322-328.e10. Pubmed, doi:10.1016/j.jaci.2017.02.036.
Slack J, Albert MH, Balashov D, Belohradsky BH, Bertaina A, Bleesing J, Booth C, Buechner J, Buckley RH, Ouachée-Chardin M, Deripapa E, Drabko K, Eapen M, Feuchtinger T, Finocchi A, Gaspar HB, Ghosh S, Gillio A, Gonzalez-Granado LI, Grunebaum E, Güngör T, Heilmann C, Helminen M, Higuchi K, Imai K, Kalwak K, Kanazawa N, Karasu G, Kucuk ZY, Laberko A, Lange A, Mahlaoui N, Meisel R, Moshous D, Muramatsu H, Parikh S, Pasic S, Schmid I, Schuetz C, Schulz A, Schultz KR, Shaw PJ, Slatter MA, Sykora K-W, Tamura S, Taskinen M, Wawer A, Wolska-Kuśnierz B, Cowan MJ, Fischer A, Gennery AR, Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and the European Society for Immunodeficiencies, Stem Cell Transplant for Immunodeficiencies in Europe (SCETIDE), Center for International Blood and Marrow Transplant Research, Primary Immunodeficiency Treatment Consortium. Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. J Allergy Clin Immunol. 2018 Jan;141(1):322-328.e10.
Journal cover image

Published In

J Allergy Clin Immunol

DOI

EISSN

1097-6825

Publication Date

January 2018

Volume

141

Issue

1

Start / End Page

322 / 328.e10

Location

United States

Related Subject Headings

  • Young Adult
  • Virus Diseases
  • Treatment Outcome
  • Prognosis
  • Mutation
  • Male
  • Kaplan-Meier Estimate
  • Infant
  • Humans
  • Hematopoietic Stem Cell Transplantation